A world-leading subscription business

(Full access for Lifetime Members only)

 Exclusive report for Lifetime Members only

 Exclusive report for Lifetime Members only

A world-leading subscription business

7 February 2022

I am not giving away too many clues about this company, because I want Undervalued-Shares.com Lifetime Members to get the best deal.

A US-based investor recently ploughed about UD 60m into the stock and bought 10% of the entire company. However, the stock got caught up in the recent tech sell-off. Now is a great opportunity to get in at an even lower price than just a few months ago.

Based on the estimates of that investor, the stock could rise 580% by 2025 and more than tenfold by 2030.

This company's business is timeless and benefits from secular trends. Over the past decade, the company has grown by 23% p.a.

I have no doubt it will emerge a long-term winner. Its stock is cheap both in relative and absolute terms.

It's a stock that is listed on one of the world's largest stock exchanges, so anyone can easily buy and sell it.

With a market cap of less than USD 500m, though, the stock has limited trading liquidity. If I disclosed it to all my readers, it could lead to a bottleneck situation in the market.

This opportunity is therefore exclusively available to Undervalued-Shares.com Lifetime Members.

Not a Lifetime Member yet? Sign up for a Membership - just USD 999/one-off.
Already a Lifetime Member? Log into your account to download the report.

l  Report updates

Not a Member yet? Sign up for a Membership.
Already a Member? Log into your account to download the report updates.

1 July 2022

Report Update (PDF - 0.2MB)

Most recent

Latest reports (for Members only)

2-2.5x from an investment holding liquidation

2-2.5x from an investment holding liquidation

This AIM-listed small-cap will likely return all its capital to shareholders. Underresearched by investors, it's an opportunity that shouldn't even exist – but it does.

Ukraine reconstruction: one stock to benefit

Ukraine reconstruction: one stock to benefit

If or when the war in Ukraine ends, this stock will likely become the focus of investor money pushing into the country.

Actinium-225, aka "the world's rarest drug"

Actinium-225, aka "the world's rarest drug"

This little-known Western European company could become the global market leader for supplying the uber-rare "Ac-225", a potent weapon to treat cancer.